Company: BIAF
Filing Date: 2025-04-22
Form Type: 424B3
Source: 0001641172-25-005598
Chunk: 71

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-22
Form: 424B3
Chunk 71
---
 market price of our Common Stock or Tradeable Warrants in
particular, will likely be subject to fluctuation, whether due to, or irrespective of, our operating results and financial condition.
The market price of our Common Stock or Tradeable Warrants may fluctuate as a result of a number of factors, some of which are beyond
our control, including, but not limited to:

| ● | actual or anticipated variations in our and our competitors’ results of operations and financial condition;                                                                                      |
| ● | market acceptance of our diagnostic tests and therapeutic products;                                                                                                                              |
| ● | the mix of products that we sell and related services that we provide;                                                                                                                           |
| ● | changes in earnings estimates or recommendations by securities analysts, if our Common Stock is covered by analysts;                                                                             |
| ● | development of technological innovations or new competitive diagnostic tests or therapeutic products by others;                                                                                  |
| ● | announcements of technological innovations or new diagnostic tests or therapeutic products by us;                                                                                                |
| ● | our failure to achieve a publicly announced milestone;                                                                                                                                           |
| ● | delays between our expenditures to develop and market new or enhanced diagnostic tests or therapeutic products and the generation of sales from those diagnostic tests and therapeutic products; |
| ● | developments concerning intellectual property rights, including our involvement in litigation;                                                                                                   |
| ● | regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified diagnostic tests or therapeutic products;                                 |
| ● | changes in the amounts that we spend to develop, acquire, or license new diagnostic tests or therapeutic products, technologies, or businesses;                                                  |
| ● | changes in our expenditures to promote our diagnostic tests or therapeutic products;                                                                                                             |
| ● | our sale or proposed sale, or the sale by our significant shareholders, of our Common Stock or other securities in the future;                                                                   |
| ● | changes in key personnel;                                                                                                                                                                        |
| ● | success or failure of our research and development projects or those of our competitors;                                                                                                         |
| ● | the trading volume of our Common Stock; and                                                                                                                                                      |
| ● | general economic and market conditions and other factors, including factors unrelated to our operating performance.                                                                              |

These factors and any corresponding price fluctuations
may materially and adversely affect the market price of our Common Stock or Tradeable Warrants and result in substantial losses being
incurred by our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities
class action litigation. If we were involved in securities litigation